Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 10/20 | 0.50 |
| ▸ | KIT | P10721 | 6/20 | 0.50 |
| ▸ | FLT3 | P36888 | 5/20 | 0.50 |
| ▸ | FLT1 | P17948 | 5/20 | 0.50 |
| ▸ | CSF1R | P07333 | 4/20 | 0.50 |
| ▸ | FLT4 | P35916 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | BLK | P51451 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830022 | 0.90 | RIPK1 (0.56) | RIPK1KDRKITFLT3NTRK1 | |
| SCHEMBL3834781 | 0.90 | RIPK1 (0.45) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3833067 | 0.88 | KDR (0.45) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3835826 | 0.87 | KDR (0.51) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3244888 | 0.87 | RIPK1 (0.42) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3831528 | 0.87 | RET (0.61) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3830989 | 0.86 | TEK (0.51) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3834274 | 0.86 | KDR (0.57) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3829919 | 0.85 | RIPK1 (0.59) | RIPK1KDRKITFLT3FLT1 | |
| SCHEMBL3833005 | 0.85 | RIPK1 (0.57) | RIPK1KDRKITFLT3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682548-B1 | PYRIDOPYRIMIDINONES FOR THE TREATMENT OF CANCER DISEASES | MERCK PATENT GMBH (DE) | 2009-09-23 | — | — | EP | claimed |
| US-7547695-B2 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2009-06-16 | — | — | US | claimed |
| US-20070099910-A1 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| US-7547695-B2 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20070203085-A1 | Methods For Interfering With Fibrosis | MERCK PATENT GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| US-20070191326-A1 | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| CN-1964705-A | Methods for interfering with fibrosis | MERCK PATENT GMBH (DE) | 2007-05-16 | — | — | CN | disclosed |
| US-20070099910-A1 | Pyridopyrimidinones | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| CN-1929831-A | Methods for altering insulin secretion | MERCK PATENT GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
| CN-1929846-A | Methods for treating neuropsychiatric disorders comprising modulating glutamate receptors with modulators of serum and glucocorticoid inducible kinases | MERCK PATENT GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203085-A1 | Methods For Interfering With Fibrosis | MMP1, SERPINA6, HDGF | RIPK1 1761/4885KDR 2990/4885KIT 795/4885 |
| US-20070099910-A1 | Pyridopyrimidinones | TIE1, FER, FLT1 | RIPK1 273/4885KDR 8/4885KIT 184/4885 |
| US-20070191326-A1 | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases | GRIK2, GRIK1, GRM2 | RIPK1 207/4885KDR 4016/4885KIT 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.